KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Debt (2017 - 2025)

Historic Non-Current Debt for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $2.6 billion.

  • Amneal Pharmaceuticals' Non-Current Debt rose 1829.33% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 1829.33%. This contributed to the annual value of $2.2 billion for FY2024, which is 939.71% down from last year.
  • Amneal Pharmaceuticals' Non-Current Debt amounted to $2.6 billion in Q3 2025, which was up 1829.33% from $2.1 billion recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Non-Current Debt registered a high of $2.7 billion during Q1 2021, and its lowest value of $2.1 billion during Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' median Non-Current Debt value was $2.6 billion (recorded in 2023), while the average stood at $2.5 billion.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Non-Current Debt tumbled by 1464.34% in 2024 and then skyrocketed by 1829.33% in 2025.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Non-Current Debt stood at $2.7 billion in 2021, then fell by 3.29% to $2.6 billion in 2022, then dropped by 7.95% to $2.4 billion in 2023, then fell by 9.4% to $2.2 billion in 2024, then increased by 18.72% to $2.6 billion in 2025.
  • Its Non-Current Debt stands at $2.6 billion for Q3 2025, versus $2.1 billion for Q2 2025 and $2.2 billion for Q1 2025.